The short answer
There is no universal interval. Re-sign a treatment-specific consent for each new procedure type and each new course of treatment, refresh the health history at every visit, and obtain a fresh good faith exam when the plan, product or patient's health changes. HIPAA authorizations run until their stated expiration date or event under 45 CFR 164.508(c).
Why is there no fixed number?
Because consent is tied to a decision, not to a calendar. Informed consent is valid for the treatment the patient actually agreed to, disclosed on the facts as they stood at the time. When the treatment changes, or the facts change, the old agreement no longer covers what you are about to do. A twelve-month rule is a useful administrative backstop, but it is not the legal test and it will not save a chart where the treatment plan changed in month three.
The reliable way to think about it is by event, with a time-based backstop layered on top.
What triggers a new signature?
| Document | Re-sign when |
|---|---|
| Treatment-specific consent | Each new procedure type; each new course or series; any change in product, technique or treatment area |
| Health history / intake | Every visit — verified and initialled, fully refreshed at least annually |
| Good faith exam and order | New treatment type, new product class, material health change, adverse event, or per your written re-exam interval |
| HIPAA Notice of Privacy Practices acknowledgment | Once, then again when the Notice is materially revised |
| Photo / marketing authorization | At its stated expiration; on revocation; when new platforms or uses are added |
| Financial and cancellation policy | When the policy changes |
Maintenance neuromodulator patients are the case most practices get wrong. A patient returning every four months for glabellar treatment is a good candidate for a per-visit consent signature, because the product, units, areas and the patient's health can all shift between visits, and the visit-by-visit signature is trivially cheap to collect. Practices that instead rely on a single consent from 2024 discover the gap only when a claim arrives.
Does re-signing ever hurt you?
Only if it becomes ritual. A patient who signs the same page at every visit without reading it, initialled by a front-desk staff member who was never in the room, produces a stack of paper that documents a process no one performed. Plaintiffs' counsel look for exactly that pattern: identical timestamps, no clinical annotation, signatures collected before the provider ever saw the patient.
The fix is to make the re-signature carry information. Have the injector or operator annotate the consent or the chart note with what was actually discussed this visit — the change in plan, the new area, the patient's question about bruising before an event, the decision to reduce units. A consent with a two-line contemporaneous clinical annotation is worth more than ten identical clean signatures.
Order matters too. The consent should be signed after the good faith exam and after the provider's discussion, not handed over with the intake clipboard at check-in. A consent signed before anyone with prescriptive authority has seen the patient cannot document a disclosure that had not yet happened.
What this means for your paperwork
Write the re-consent policy down and make it specific by service line: which services require per-visit consent, which require per-course, which require annual refresh. Name the person responsible for verifying it before treatment begins, and build the check into the treatment record rather than the scheduling system.
Version-control every form. Put a version number and revision date in the footer, archive superseded versions rather than overwriting them, and keep a change log — because a claim is judged against the form in force on the treatment date. Retain HIPAA documentation, including authorizations, for at least six years under 45 CFR 164.530(j)(2), and retain clinical consents under your state's medical record retention period, which is usually longer.
Set a standing annual review of the whole form set, plus an out-of-cycle review whenever FDA labeling changes, your state board issues new guidance, or you add a product, device or treatment area.
Related questions
This answer is educational and is not legal or medical advice. Requirements vary by state and change over time — verify with your own legal and clinical advisors before applying anything here in practice.